Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used in Tunisia to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The market for these drugs in Tunisia has been growing steadily in recent years, driven by various factors.
Customer preferences: Tunisian customers prefer bronchodilator drugs that are effective and affordable. They tend to choose drugs that have fewer side effects and are easy to use. Customers also prefer drugs that are available in different forms such as inhalers, tablets, and syrups.
Trends in the market: One of the major trends in the bronchodilator drugs market in Tunisia is the increasing prevalence of respiratory diseases. This is due to various factors such as air pollution, smoking, and genetic predisposition. As a result, the demand for bronchodilator drugs is expected to continue to grow in the coming years.Another trend in the market is the increasing availability of generic bronchodilator drugs. This has led to increased competition among drug manufacturers, resulting in lower prices for customers. The availability of generic drugs has also made it easier for customers to access these drugs, especially in rural areas.
Local special circumstances: Tunisia has a high prevalence of smoking, which is a major risk factor for respiratory diseases. The government has implemented various measures to reduce smoking rates, including increasing taxes on tobacco products and implementing smoking bans in public places. These measures are expected to reduce the prevalence of respiratory diseases in the long term.
Underlying macroeconomic factors: Tunisia's healthcare system is undergoing significant reforms, which are expected to improve access to healthcare services, including bronchodilator drugs. The government is investing in healthcare infrastructure and increasing funding for healthcare services. This is expected to increase the availability of bronchodilator drugs in the country.In conclusion, the bronchodilator drugs market in Tunisia is expected to continue to grow in the coming years, driven by increasing demand for these drugs due to the high prevalence of respiratory diseases. The availability of generic drugs and government measures to reduce smoking rates are expected to further boost the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
